Biogen’s Opt-In On Roche’s CD20 Drugs Is Gift That Keeps On Giving
Royalties From Blockbuster Portfolio Amount To Billions
Roche has enjoyed decades-long success with its string of CD20-targeting drugs – and thanks to a legacy opt-in, so has Biogen.
You may also be interested in...
Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio
Roche has gained approval for the first of its two bispecific therapies for lymphoma, but will face stiff competition from Genmab and AbbVie’s late-stage rival.
As Tecentriq Growth Slows, Roche’s Imminent TIGIT Readout Is Crucial
One of the year’s most important trial readouts is for Roche’s potential first-in-class TIGIT inhibitor, tiragolumab, and could help reverse a slowdown in blockbuster immunotherapy Tecentriq's growth.
EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody
If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.